Companies /Healthcare
Recursion Pharmaceuticals Inc - Class A
NASDAQ: RXRX Biotechnology
$3.50
▼ $0.38 (−9.79%) today
Markets closed · 9:27pm ET

Recursion Pharmaceuticals (RXRX) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
71%
EPS beat rate
+5.36%
Avg. EPS surprise
Consecutive EPS beats
RXRX vs Market · 30-day return after each reportRXRXS&P 500
−20%0%−3.9%+5.2%Q1 25−16.6%+3.1%Q2 25−2.8%+0.9%Q3 25−22.0%−8.5%Q4 25−3.2%+0.7%Q1 26+14.5%+0.1%Q2 26
−20%0%Q1 25Q3 25Q1 26
RXRX EPS Trend · estimate vs actualEstimateActual
$-0.40$-0.20$-0.52$-0.50Q1 25$-0.35$-0.41Q2 25$-0.38$-0.36Q3 25$-0.32$-0.21Q4 25$-0.26$-0.22Q1 26$-0.23$-0.25Q2 26$-0.23$-0.22Q3 26
$-0.40$-0.20Q1 25Q3 25Q1 26Q3 26
RXRX Revenue Trend · estimate vs actualEstimateActual
$0$10.0M$20.0M$30.0M$18.1M$14.7MQ1 25$15.4M$19.2MQ2 25$19.4M$5.2MQ3 25$24.6M$35.5MQ4 25$15.8M$6.5MQ1 26$12.0M$7.7MQ2 26$14.8M$18.6MQ3 26
$0$10.0M$20.0M$30.0MQ1 25Q3 25Q1 26Q3 26

How Often Does Recursion Pharmaceuticals Beat Earnings Estimates?

Recursion Pharmaceuticals beat EPS estimates in 5 of its last 7 reported quarters.

RXRX quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Quarter includes a $10.0 million Sanofi milestone payment recognized in collaboration revenue; prior-year quarter included $22.8 million of in-process R&D costs for REC-102 that did not recur. $-0.22 est. $-0.23 +3.85% $18.6M est. $14.8M +25.25%
Q2 2026 $-0.25 est. $-0.23 −6.84% $7.7M est. $12.0M −35.89%
Q1 2026 $-0.22 est. $-0.26 +14.43% $6.5M est. $15.8M −58.98%
Q4 2025 $-0.21 est. $-0.32 +33.35% $35.5M est. $24.6M +44.71%
Q3 2025 $-0.36 est. $-0.38 +5.69% $5.2M est. $19.4M −73.27%
Q2 2025 $-0.41 est. $-0.35 −16.05% $19.2M est. $15.4M +24.96%
Q1 2025 $-0.50 est. $-0.52 +3.10% $14.7M est. $18.1M −18.46%

Figures from SEC filings and company reports. Not investment advice.